Egalet Corporation announced positive top-line results from a phase 3 study evaluating the safety of Egalet-002, an abuse-deterrent, extended-release oxycodone developed using a unique application of the Guardian Technology. Egalet-002 was generally well-tolerated and the incidence of adverse events reported was generally consistent with outcomes expected following treatment with an extended-release oxycodone formulation.